Enhertu Gets Accelerated FDA Approval for 2nd Line NSCLC Use

Daiichi Sankyo’s and AstraZeneca’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has obtained accelerated approval from the US FDA for the second-line treatment of HER2 mutant non-small cell lung cancer (NSCLC). The two companies said on August 11 that the drug...read more